MARKET WIRE NEWS

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

Source: SeekingAlpha

2025-08-13 11:36:21 ET

DiaMedica Therapeutics Inc. (DMAC)

Q2 2025 Earnings Conference Call

August 13, 2025, 8:00 AM ET

Company Participants

Dietrich John Pauls - President, CEO & Director

Julie Krop - Chief Medical Officer

Scott Kellen - CFO & Corporate Secretary

Conference Call Participants

Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division

Thomas Flaten - Lake Street Capital Markets, LLC, Research Division

Presentation

Operator

Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Q2 2025 Earnings Conference Call. An audio recording of this webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section. Before the company proceeds with its remarks, please note that the company will be making forward-looking statements on today's call. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. More information, including factors that could cause actual results to differ from projected results appears in the section entitled Cautionary Statement Note regarding forward-looking statements in the company's press release issued yesterday and under the heading Risk Factors in DiaMedica's most recent annual report on Form 10-K and most recent quarterly report on Form 10-Q....

Read the full article on Seeking Alpha

For further details see:

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript
DiaMedica Therapeutics Inc.

NASDAQ: DMAC

DMAC Trading

-5.35% G/L:

$7.07 Last:

92,570 Volume:

$7.32 Open:

mwn-link-x Ad 300

DMAC Latest News

DMAC Stock Data

$439,533,585
29,684,140
16.95%
29
N/A
Biotechnology & Life Sciences
Healthcare
US
Minneapolis

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App